Brown Advisory Inc. Has $68.38 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Brown Advisory Inc. cut its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 1.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 117,303 shares of the company's stock after selling 2,281 shares during the period. Brown Advisory Inc.'s holdings in Eli Lilly and Company were worth $68,378,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Independent Advisor Alliance increased its holdings in Eli Lilly and Company by 1.7% in the fourth quarter. Independent Advisor Alliance now owns 32,269 shares of the company's stock valued at $18,810,000 after purchasing an additional 544 shares during the period. Summit X LLC increased its holdings in Eli Lilly and Company by 17.7% in the fourth quarter. Summit X LLC now owns 3,658 shares of the company's stock valued at $2,134,000 after purchasing an additional 549 shares during the period. Allegheny Financial Group LTD increased its holdings in Eli Lilly and Company by 3.5% in the fourth quarter. Allegheny Financial Group LTD now owns 3,415 shares of the company's stock valued at $1,990,000 after purchasing an additional 116 shares during the period. Financial Advocates Investment Management increased its holdings in Eli Lilly and Company by 1.3% in the fourth quarter. Financial Advocates Investment Management now owns 6,725 shares of the company's stock valued at $3,920,000 after purchasing an additional 85 shares during the period. Finally, NorthRock Partners LLC increased its holdings in Eli Lilly and Company by 3.4% in the fourth quarter. NorthRock Partners LLC now owns 5,350 shares of the company's stock valued at $3,119,000 after purchasing an additional 176 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 0.1 %

NYSE LLY traded down $1.12 during trading hours on Friday, hitting $770.00. The company's stock had a trading volume of 1,670,317 shares, compared to its average volume of 2,877,174. Eli Lilly and Company has a 52 week low of $419.80 and a 52 week high of $800.78. The company has a market capitalization of $731.81 billion, a PE ratio of 113.40, a price-to-earnings-growth ratio of 1.53 and a beta of 0.37. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The company's 50-day simple moving average is $760.66 and its two-hundred day simple moving average is $685.22.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business had revenue of $8.77 billion for the quarter, compared to analysts' expectations of $8.94 billion. During the same quarter last year, the firm earned $1.62 EPS. The firm's revenue for the quarter was up 26.0% compared to the same quarter last year. Research analysts anticipate that Eli Lilly and Company will post 13.82 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Shareholders of record on Thursday, May 16th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Wednesday, May 15th. This represents a $5.20 annualized dividend and a yield of 0.68%. Eli Lilly and Company's dividend payout ratio (DPR) is 76.58%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. Cantor Fitzgerald restated an "overweight" rating and issued a $885.00 price objective (up from $815.00) on shares of Eli Lilly and Company in a report on Tuesday, April 30th. Argus upped their price target on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a "buy" rating in a research report on Tuesday. DZ Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating and set a $820.00 price target on the stock. in a research report on Wednesday, February 21st. Truist Financial upped their price target on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the company a "buy" rating in a research report on Wednesday, May 1st. Finally, TheStreet raised shares of Eli Lilly and Company from a "c+" rating to a "b" rating in a research report on Friday, March 8th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus target price of $769.53.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.